KALRAY
5.7.2022 18:02:03 CEST | Business Wire | Press release
Clever Cloud , a European provider of automation and optimization solutions for websites and applications hosting, and Kalray (Paris:ALKAL) (Euronext Growth Paris: ALKAL), a leading provider of a new generation of processors and acceleration cards specialized in Intelligent Data Processing from Cloud to Edge, announce a partnership aimed at strengthening the relationship between the two companies for the deployment of next-generation storage solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220705005197/en/
Clever Cloud, which is currently setting up in a third Parisian data center and strengthening its technical platform, has chosen to partner with French company Kalray and its Flashbox™, a new generation of NVMe storage array that can accommodate up to 24 PCI Express (NVMe) SSDs, for its high-performance storage solution.
PERFORMANCE, RESILIENCE AND OPENNESS
Without a host CPU (Central Processing Unit), the Flashbox™ leverages K200-LP™ accelerator cards featuring the Coolidge™ DPU (Data Processing Unit) that takes advantage of the unique and patented MPPA® (Massively Parallel Processor Array) architecture developed by Kalray. This chip takes advantage of the power of 80 parallel cores and enables data centers adopting NVMe SSD storage to remove bottlenecks and improve performance, while consuming minimal power and resources.
A unique concept on the market today, the Flashbox™ as proposed by Kalray benefits from ultra-fast interfaces and low power consumption. It can deliver up to 12 million IOPS through a 2x 100 Gb/s network interface and is based on market standards such as Storage Performance Development Kit (SPDK), NVMe/TCP or RDMA over Converged Ethernet (RoCEv1/v2). It will eventually be offered by storage vendors using Kalray cards.
"Kalray's solution meets all our needs and the criteria that are important to us, whether in terms of sovereignty, openness, resilience, energy efficiency or performance ," said Quentin Adam, CEO of Clever Cloud.
The Flashbox™ is currently being tested in Clever Cloud's infrastructure and will join its new Paris data center where it will work alongside the latest generation of compute servers Clever Cloud is installing there. It will enable Clever Cloud to offer greater flexibility to its customers in managing storage, but also to support the launch of new offerings.
This is part of the development of Clever Cloud's Storage API, which allows various storage sources, whether local, remote or via third-party cloud service providers, to be simply allocated to the virtual machines that host users' applications. This open, multi-cloud approach is what makes Clever Cloud so successful.
CLEVER CLOUD AND KALRAY: FOR A “MADE IN FRANCE” R&D
Clever Cloud and Kalray are also partnering in several projects where they are working closely together to leverage Kalray's K200-LP™ cards as accelerators to offload Clever Cloud's network layer functionalities or computations related to the protection and redundancy of data stored within Clever Cloud's servers.
"The collaboration with Kalray is not just about two French companies that have an interest in working together, but about two projects that have, at their heart, the creation of value through innovation, where the partnership is also between the technical teams," adds Steven Le Roux, CTO of Clever Cloud .
“We are very pleased to be working with Clever Cloud, with whom we share common values, both in terms of innovation and the philosophy of our solutions, which are designed to be easy to use, flexible, scalable and open.
Kalray has a unique position in Europe in this market of very high-performance and low-power processors. We are proud to be able to build innovative French storage solutions with Clever Cloud and thus contribute to the technological sovereignty of France and Europe” , declares Eric Baissus, President and CEO of Kalray .
The Flashbox™ will be showcased at the upcoming Flash Memory Summit, a major event in the field, from August 2 to 4, 2022, in Santa Clara Convention Center, CA, USA (booth #940).
ABOUT CLEVER CLOUD
Founded in 2010, Clever Cloud is a company based in Nantes, France, and specialized in IT automation. It creates and provides the software building blocks necessary for the flexible deployment of applications on self-service PaaS architectures. Its clients include such major names as Airbus, AXA, Caisse d'Épargne, Cegid, Docaposte, MAIF, McDonald's, Solocal, SNCF, TBWA...
Website: https://www.clever-cloud.com
Latest news: https://www.clever-cloud.com/blog
ABOUT KALRAY
Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is a fabless semiconductor company, a leading provider of a new class of processors, specialized in Intelligent Data Processing from Cloud to Edge. Kalray’s team have created and developed its leading-edge technology and products to help its clients maximize the market possibilities presented by a world dominated by massive, disparate and pervasive data.
Thanks to Kalray’s patented manycore architecture, Kalray’s MPPA® Intelligent Data Processors are natively capable of managing multiple workloads with no bottlenecks to enable smarter, more efficient and energy-wise data-intensive applications. Kalray's offering includes processors, acceleration cards with associated software environment and appliances, allowing its customers to design the best solutions in fast growing sectors such as modern data centers, 5G, AI and Edge Computing, autonomous vehicles and others.
Founded in 2008 as a spin-off of CEA French lab, with investors such as Alliance Venture (Renault-Nissan-Mitsubishi), Safran, NXP Semiconductors, CEA and Bpifrance, Kalray is dedicated through technology, expertise and passion to offer more: More for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005197/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom